Harbor Capital Advisors Inc. Invests $399,000 in Celcuity, Inc. $CELC

Harbor Capital Advisors Inc. purchased a new stake in Celcuity, Inc. (NASDAQ:CELC) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 8,071 shares of the company’s stock, valued at approximately $399,000.

Several other institutional investors also recently bought and sold shares of the business. BNP Paribas Financial Markets increased its position in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Celcuity by 211.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock worth $74,000 after purchasing an additional 3,766 shares during the period. AlphaQuest LLC increased its holdings in Celcuity by 176.3% in the 2nd quarter. AlphaQuest LLC now owns 7,087 shares of the company’s stock valued at $95,000 after purchasing an additional 4,522 shares in the last quarter. XTX Topco Ltd purchased a new position in Celcuity in the second quarter valued at about $169,000. Finally, Corton Capital Inc. acquired a new position in shares of Celcuity during the second quarter worth about $175,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Celcuity

In other news, Director Richard E. Buller sold 3,000 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $105.69, for a total value of $317,070.00. Following the sale, the director owned 6,760 shares in the company, valued at approximately $714,464.40. This represents a 30.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 15.78% of the company’s stock.

Analyst Upgrades and Downgrades

CELC has been the subject of a number of recent research reports. Craig Hallum increased their target price on Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Jefferies Financial Group upped their price target on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Needham & Company LLC set a $95.00 price objective on shares of Celcuity in a research note on Monday, October 20th. Wolfe Research began coverage on shares of Celcuity in a research report on Tuesday, November 18th. They set an “outperform” rating and a $110.00 target price on the stock. Finally, Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $105.25.

Celcuity Price Performance

CELC stock opened at $102.25 on Monday. The stock’s 50 day moving average is $90.55 and its two-hundred day moving average is $55.97. Celcuity, Inc. has a 52-week low of $7.57 and a 52-week high of $112.64. The company has a market capitalization of $4.73 billion, a PE ratio of -27.86 and a beta of 0.21. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. Analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.